{"id":"W3009722442","doi":"10.1200/jco.2007.25.18_suppl.4028","title":"Bevacizumab (Bev) in combination with XELOX or FOLFOX4: Updated efficacy results from XELOX-1/ NO16966, a randomized phase III trial in first-line metastatic colorectal cancer","year":2007,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Treatment and Pharmacology","field":"Medicine","cited_by":114,"is_retracted":false,"has_abstract":true,"ca_institutions":"CancerCare Manitoba","funders":"","keywords":"Oxaliplatin; Medicine; FOLFOX; Capecitabine; Bevacizumab; Internal medicine; Oncology; Regimen; Colorectal cancer; Chemotherapy; Fluorouracil; Chemotherapy regimen; Cancer","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.004012509,0.001157337,0.001965323,0.00040161,0.000231754,0.000871046,0.0007917503,0.0008009761,0.00243434],"category_scores_gemma":[0.002188448,0.0004390753,0.001431294,0.000468275,0.0004965741,0.0005404279,0.0004201286,0.00208931,0.0004225234],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0006557957,"about_ca_system_score_gemma":0.001058733,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0007895796,"about_ca_topic_score_gemma":0.00233549,"domain_scores_codex":[0.998727,0.0008337866,0.00006496063,0.0001008993,0.0001659844,0.0001072776],"domain_scores_gemma":[0.9986796,0.0003682098,0.0004111038,0.00006544067,0.000072823,0.0004027754],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.8050282,0.01282751,0.0069388,0.002403809,0.0037327,0.0001511865,0.0001308279,0.002613414,0.014187,0.0003051542,0.005502664,0.1461787],"study_design_scores_gemma":[0.8258559,0.147224,0.01661086,0.0001511401,0.002201958,0.0002944083,0.00003050364,0.001038566,0.001505447,0.0002478322,0.004796285,0.00004307031],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.962712,0.02541573,0.001249438,0.001231554,0.0003485459,0.002424805,0.003137208,0.0001271805,0.003353668],"genre_scores_gemma":[0.9722962,0.01122756,0.002216249,0.001328659,0.0004080118,0.001636975,0.008408604,0.00005004077,0.002427773],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.004012509,"threshold_uncertainty_score":0.02122045,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1315895413467038,"score_gpt":0.5133118688873759,"score_spread":0.3817223275406721,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}